An Jin, Lee Hannah, Lee Jeongmi, Kang Sung-Yoon, Yang Min-Suk, Song Woo-Jung, Kim Sae-Hoon, Kim Tae-Bum
Department of Pulmonary, Allergy and Critical Care Medicine, College of Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University, Seoul, Republic of Korea.
Research Institute of The Way Healthcare, Seoul, Republic of Korea.
J Thorac Dis. 2024 Sep 30;16(9):6150-6160. doi: 10.21037/jtd-23-1744. Epub 2024 Sep 3.
Limited data are available on the prescription patterns and efficacy of antitussives and expectorants for patients with acute and chronic cough. This study examined the use and efficacy of these medications in a nationally representative sample of Korean patients.
We examined 4,206,016 individuals from the National Health Insurance Service (NHIS)-National Health Information Database (NHID) between 2015 and 2017. Among them, a sample of 10% (n=420,602) was retrieved for the diagnosis of respiratory diseases using the International Classification of Diseases, 10 edition (ICD-10; J00-J99), or the prescription of antitussives and expectorants for cough (ICD-10; R05). The acute cough group included those who were prescribed medications within 4 weeks of initial diagnosis (prescription within 14 days), whereas the chronic cough group included patients who were prescribed medications within 16 weeks of initial diagnosis (prescription within 56 days). If the prescription was discontinued or not changed to an alternative drug after the initial prescription, these cases were considered to have achieved symptom relief.
This study included 288,460 patients (971,065 cases) with acute cough and 5,888 patients (15,399 cases) with chronic cough. 'Expectorants, excluding combinations with cough suppressants' had the highest prescription rates in both groups (acute cough, 63.8%; chronic cough, 61.7%), and showed the highest symptom relief regardless of the number of medications prescribed (acute cough, 84.3%; chronic cough, 70.4%).
'Expectorants, excluding combinations with cough suppressants' were the most prescribed and effective medications for relieving cough symptoms in Korea patients. Further studies are needed to determine the optimal duration for using antitussives and expectorants in cough management.
关于镇咳药和祛痰药用于急慢性咳嗽患者的处方模式及疗效的数据有限。本研究在具有全国代表性的韩国患者样本中考察了这些药物的使用情况及疗效。
我们研究了2015年至2017年间来自国民健康保险服务(NHIS)-国民健康信息数据库(NHID)的4,206,016个人。其中,抽取10%的样本(n = 420,602),使用国际疾病分类第10版(ICD-10;J00-J99)诊断呼吸系统疾病,或使用镇咳药和祛痰药治疗咳嗽(ICD-10;R05)。急性咳嗽组包括在初次诊断后4周内(14天内)开具药物处方的患者,而慢性咳嗽组包括在初次诊断后16周内(56天内)开具药物处方的患者。如果初次处方后停药或未更换为其他药物,则这些病例被视为症状缓解。
本研究纳入了288,460例急性咳嗽患者(971,065例次)和5,888例慢性咳嗽患者(15,399例次)。“不包括与止咳药联用的祛痰药”在两组中的处方率最高(急性咳嗽,63.8%;慢性咳嗽,61.7%),并且无论开具药物的数量多少,其症状缓解率均最高(急性咳嗽,84.3%;慢性咳嗽,70.4%)。
“不包括与止咳药联用的祛痰药”是韩国患者中最常处方且有效的缓解咳嗽症状的药物。需要进一步研究以确定在咳嗽管理中使用镇咳药和祛痰药的最佳疗程。